Satraplatin: Leading the new generation of oral platinum agents

Expert Opinion on Investigational Drugs

Volumn 18, Issue 11, 2009, Pages 1787-1797

  Bhargava, Ashish ^a   Vaishampayan, Ulka N ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Hudson Webber Cancer Research Center   (United States)

Author keywords

JM 216; Oral platinum; Platin; Prostate cancer; Satraplatin

Indexed keywords

BEVACIZUMAB; CAMPTOTHECIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ETOPOSIDE; FOLINIC ACID; GEMCITABINE; JM 383; JM 518; JM 559; MITOXANTRONE; PACLITAXEL; PLATINUM AMMINE CYCLOHEXYLAMINE DICHLORIDE; PLATINUM COMPLEX; PREDNISOLONE; PREDNISONE; SATRAPLATIN; TETRAPLATIN; UFT; UNCLASSIFIED DRUG;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; DATA BASE; DIARRHEA; DRUG ACTIVITY; DRUG APPROVAL; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HUMAN; HYPERGLYCEMIA; INFECTION; LEUKOPENIA; LUNG CANCER; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MEDICAL LITERATURE; MEDICAL SOCIETY; MEDLINE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT INDICATION; UTERINE CERVIX CANCER; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 73849133671     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903362437     Document Type: Review

References (71)

1. Trazaska S. Cisplatin. Chem Eng News 2005;83:65
2. Harrap KR. Preclinical studies identifying Carboplatin as a viable cisplatin alternative. Cancer Treat Rev 1985;12:21-33
3. De Gramont A, Figer A, Metal S. Leucovorin and fluorouracil with or without Oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947
4. Giacchetti S, Perpoint B, Zidani N, et al. Phase III multicenter randomized trial of Oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-147
5. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of Oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin interim results of a Phase III trial. J Clin Oncol 2003;21:2059-2069
6. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and Oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-29
7. Kelland LR. Overcoming resistance to platinum therapy in patients with advanced cancer. Am J Cancer 2002;1:247-255
8. Ho YP, Au-Yeung SC, To KK. Platinum based anticancer agents: innovative design strategies and biological perspectives. Med Res Rev 2003;23:633-655
9. Harrap KR, Murrer BA, Giandomenico C, et al. Ammine/amine platinum IV dicarboxylates: a novel class of complexes which circumvent intrinsic cisplatin resistance. In: Howell SB, editor, Platinum and other metal coordination complexes in cancer chemotherapy. Plenum New York; 1991. p. 391-399
10. Kelland LR. An update on Satraplatin: the first orally available platinum anticancer drug. Expert Opin Investig Drugs 2000;9:1373-1382
11. Giandomenico CM, Abrams MJ, Murrer BA, et al. Synthesis and reactions of a new class of orally active PT (IV) antitumor complexes. In: Howell SB, editor, Platinum and other metal co-ordination compounds in cancer chemotherapy. Plenum Press, New York, USA; 1991. p. 93
12. Eun Ju Lee, Moo-Jin Jun, Youn Soo Sohn. Synthesis and properties of Novel Platinum Complexes involving asymmetric chiral diamines as carrier ligands. Bull Korean Chem Soc 1999;20:1295-1298
13. Choy H. Satraplatin: an orally available platinum analog for the treatment of cancer. Expert Rev Anticancer Ther 2006;6:973-982
14. Mellish KJ, Barnard CF, Murrer BA, et al. DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. Int J Cancer 1995;62:717-723
15. O'Neill CF, Koberle B, Masters JR, et al. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Br J Cancer 1999;81:1294-1303
16. Wosikowski K, Caligiuri M, Rattel B, et al. Efficacy of satraplatin (JM216) and its metabolites is maintained in taxanes-resistant tumors. Proceedings of the First International Conference on Cancer Therapeutics: Molecular Targets, Pharmacology and Clinical Applications; 2004
17. Vaisman A, Lim S, Patrick SM, et al. Effect of DNA polymerases and high mobility group protein I on the carrier ligand specificity of translesion synthesis past platinum-DNC adducts. Biochemistry 1999;38:11026-11039
18. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-4886 (Pubitemid 26374423)
19. Wei M, Cohen SM, Silverman AP, et al. Effets of spectator ligands on the specific recognition of intrastrand platinum- DNA cross-links by high mobility group box and TATA-binding proteins. J Biol Chem 2001;276:38774-38780
20. Kelland LR, Abel G, McKeage MJ, et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug. Cancer Res 1993;53:2581-2586
21. Mellish KJ, Kelland LR, Harrap KR. In vitro platinum drug chemo-sensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 1993;68:240-250
22. Twentyman PR, Wright KA, Mistry P, et al. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 1992;52:5674-5680
23. Wosikowski K, Lamphere L, Unteregger G, et al. Preclinical antitumor activiy of the oral platinum analog satraplatin. Cancer Chemother Pharmacol 2007;60:589-600
24. Goddard PM, Valenti MR, Harrap KR. The role of murine tumor models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumor agents: a cautionary note. Ann Oncol 1991;2:535-540
25. McKeage MJ, Kelland LR, Boxall FE, et al. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum (IV) (JM216) in vivo. Cancer Res 1994;54:4118-4122
26. Rose WC. Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models. Cancer Chemother Pharmacol 1997;40:51-56
27. Amorino GP, Mohr PJ, Hercules SK, et al. Combined effects of the orally active cisplatin analogue, JM216 and radiation therapy in antitumor therapy. Cancer Chemother Pharmacol 2000;46:423-426
28. McKeage MJ, Mistry P, Ward J, et al. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single dose administration. Cancer Chemother Pharmacol 1995;36:451-458
29. McKeage MJ, Raynaud F, Ward J, et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997;15:2691-2700
30. Raynaud FI, Boxall FE, Goddard P, et al. Metabolism, protein binding and in vivo activity of the oral platinum drug JM 216 and its biotransformation products. Anticancer Res 1996;16:1857-1862
31. Raynaud FI, Mistry P, Donaghue A, et al. Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol 1996;38:155-162
32. Kelland L. Broadening the clinical use of platinum drug-based chemotherapy with new analogues: satraplatin and picoplatin. Expert Opin Investig Drugs 2007;16:1009-1021
33. Carr JL, Tingle MD, Mekeage MJ. Rapid biotransformation of satraplatin by human red blood cells in vivo. Cancer Chemother Pharmacol 2002;50:9-15
34. Carr JL, Tingle MD, McKeage MJ. Satraplatin activation by hemoglobin, cytochrome C and liver microsomes in vitro. Cancer Chemother Pharmacol 2006;57:483-490
35. Raynaud FI, Odell DE, Kelland LR. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels. Br J Cancer 1996;74:380-386
36. Ando Y, Shimizu T, Nakamura K, et al. Potent and non specific inhibition of cytochrome P450 by JM216, a new oral platinum agent. Br J Cancer 1998;78:1170-1174
37. Beale P, Raynaud F, Hanwell J, et al. Phase I study of oral JM216 given twice daily. Cancer Chemother Pharmacol 1998;42:142-148
38. Sessa C, Minoia C, Ronchi A, et al. Phase I clinical and pharmacokinetic study of the oral platinum analog JM216 given daily for 14 days. Annals Oncol 1998;9:1315-1322
39. Kurata T, Tamura T, Sasaki Y, et al. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum (IV) (JM216) administered once a day for five consecutive days: a phase I study. Jpn J Clin Oncol 2000;30:377-384
40. Fokkema E, de Vries EG, Meijer S, et al. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients. Cancer Chemother Pharmacol 2000;45:89-92
41. Hoffman P, Mauer A, Haraf D, et al. Oral JM216 plus concomitant radiotherapy (RT) for patients (pts) with advanced malignancies of the chest. Proc ASCO 1998;17:488a
42. Cmelak AJ, Choy H, Murphy BA, et al. Phase I study of JM216 with concurrent radiation in non-small cell lung cancer and squamous cell head and neck cancer. Proc ASCO 1999;18:393a
43. Jones SF, Greco FA, Hainsworth JD, et al. Phase I study of JM216 in combination with paclitaxel in patients with advanced malignancies. Proc ASCO 1999;18:216
44. Demario MD, Ratain MJ, Vogelzang NJ, et al. A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro- cyclohexylamine-platinum IV (216) each given over 14 days every 28 days. Cancer Chemother Pharmacol 1999;43:385-388
45. Judson I, Cerny T, Epelbaum R, et al. Phase II trial of the oral platinum complex JM216 in non-small cell lung cancer: an EORTC early clinical studies group investigation. Ann Oncol 1997;8:604-606
46. Schrump DS, Altorki NK, Henschke CL, et al. Non-small cell lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors, Cancer: principles and practice of oncology. 7th edition. Lippincot Williams & Wilkins, PA, USA; 2005. p. 753-810
47. Fokkema E, Groen HJ, Bauer J, et al. Phase II study of oral platinum drug JM216 as first line treatment in patients with small cell lung cancer. J Clin Oncol 1999;17:3822-3827
48. Grant SC, Gralla RJ, Kris MG, et al. Single-agent chemotherapy trials in small -cell lung cancer, 1970 to 1990: the case for studies in previously treated patients. J Clin Oncol 1992;10:484-498
49. Bristol-Myers Squibb Report: 1998 Jun 9. Accession No. 910068667. A randomized phase II study of satraplatin (JM216) or standard platinum therapy in patients with late relapses of epithelial ovarian cancer (CA 142-006)
50. Smith JW, McIntyre KJ, Acevedo PJ, et al. Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer. Breast Cancer Res Treat 2009;118:361-367
51. Trudeau M, Stuart G, Hirte H, et al. A phase II trial of JM-216 in cervical cancer: an NCIC CTG study. Gynecol Oncol 2002;84:327-331
52. Muthuramalingam SR, Patel K, Protheroe A. Management of patients with hormone refractory prostate cancer. Clin Oncol (R Coll Radiol) 2004;16:505-516
53. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520
54. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512
55. Latif T, Wood L, Connell C, et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily for 5 days in hormone refractory prostate cancer (HRPC). Invest New Drugs 2005;23:79-84
56. Sternberg CN, Whelan P, Hetherington J, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs prednisone alone in patients with hormone refractory prostate cancer. Oncology 2005;68:2-9
57. Sternberg CN, Hetherington J, Paluchowska B, et al. Randomized phase III trial of a new oral platinum, satraplatin (JM-216) plus prednisone or prednisone alone in patients with hormone refractory prostate cancer [abstract 1586]. Proc Am Soc Clin Oncol 2003;22:395
58. Armstrong A, George DJ. Satraplatin in the treatment of hormone refractory metastatic prostate cancer. Ther Clin Risk Manag 2007;3:877-883
59. Petrylak DP, Sartor OA, Witjes JA, et al. A Phase III randomized double blind trial of satraplatin and prednisone vs placebo and prednisone for patients with hormone refractory prostate cancer (HRPC) [abstract #145]. Proc Am Soc Clin Oncol Prostate Cancer Symp 2007
60. Sartor OA, Petrylak DP, Witjes JA, et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial. Proc Am Soc Clin Oncol, May 2008, Chicago, IL, USA.; 26: Abstract 5003.
61. Petrylak DP, Sartor AO, Witjes F, et al. Satraplatin in patients with advanced hormone-referactory prostate cancer (HRPC): Overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial. Feb 2009 GU ASCO symposium,Orlando, FL, USA. Abstract 163
62. Vaishampayan U, Heilbrun L, Smith D, et al. Phase II trial of satraplatin, prednisone and bevacizumab in metastatic castrate resistant prostate cancer pretreated with docetaxel. Feb 2009 GU ASCO symposium, Orlando, FL, USA. Abstract 190
63. Papatsoris AG, Karamouzis MV, Papavassiliou AG. Novel biological agents for the treatment of Hormone-Refractory Prostate Cancer (HRPC). Curr Med Chem 2005;12:277-296
64. Garmey EG, Sartor O, Halabi S, et al. Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clin Adv Hematol Oncol 2008;6:118-22, 127-132
65. Azuma K, Komohara Y, Sasada T, et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 2007;98:1336-1343
66. Azuma K, Sasada T, Kawahara A, et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 2009;6:326-333
67. Sessa C, Hess D, Bauer J, et al. J Clin Oncol 26: 2008 ASCO Annual Meeting, (May 20 supplement; abstr 2560)
68. Wisinski K, Mulcahy M, Kuzel TM, et al. J Clin Oncol 26: 2008 ASCO Annual Meeting, (May 20 supplement; abstr 13554)
69. Paola D, Alonso S, Alessio D, et al. J Clin Oncol 27, 2009 ASCO Annual Meeting (abstr e13534)
70. Leal TB, Wilding G, Eickhoff J, et al. J Clin Oncol 26: 2008 ASCO Annual Meeting. May 20 supplement (abstract 2570)
71. Thompson DS, Spigel DR, Hainsworth JD, et al. J Clin Oncol 26: 2008 ASCO Annual Meeting, (May 20 supplement; abstr 19023)